Outcomes of Thalassemia Patients Undergoing Hematopoietic Stem Cell Transplantation by Using a Standard Myeloablative versus a Novel Reduced-Toxicity Conditioning Regimen According to a New Risk Stratification

• Main Authors: Anurathapan,U., Pakakasama,S., Mekjaruskul,P., Sirachainan,N., Songdej,D., Chuansumrit,A., Charoenkwan,P., Jetsrisuparb,A., Sanpakit,K., Pongtanakul,B., Rujkijyanont,P., Meekaewkunchorn,A., Sruamsiri,R., Ungkanont,A., Issaragrisil,S., Andersson,B.S., Hongeng,S.
• Format: Article
• Published: Elsevier Inc. 2015
• Subjects: Transplantation; Hematology; Medicine (all)
• Online Access: http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84912110334&origin=inward; http://cmuir.cmu.ac.th/handle/6653943832/38340
• Institution: Chiang Mai University

© 2014 American Society for Blood and Marrow Transplantation. Improving outcomes among class 3 thalassemia patients receiving allogeneic hematopoietic stem cell transplantations (HSCT) remains a challenge. Before HSCT, patients who were ≥ 7 years old and had a liver size ≥ 5 cm constitute what the C...